Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia

Cell Death and Differentiation

Volumn 14, Issue 9, 2007, Pages 1667-1677

  Kuroda, J ^a   Kimura, S ^b   Strasser, A ^c   Andreeff, M ^d   O'Reilly, L A ^c   Ashihara, E ^b   Kamitsuji, Y ^b,e   Yokota, A ^b   Kawata, E ^b,e   Takeuchi, M ^b,f   Tanaka, R ^b   Tabe, Y ^g   Taniwaki, M ^a   Maekawa, T ^b  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d UNIVERSITY OF TEXAS   (United States)

^e KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^f SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^g JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ANTILEUKEMIC AGENT; BCR ABL PROTEIN; BH3 PROTEIN; BIM PROTEIN; BORTEZOMIB; HEAT SHOCK PROTEIN 90 INHIBITOR; IMATINIB; INNO 406; ONCOPROTEIN; PROTEIN BAD; PROTEIN BIK; PROTEIN BMF; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL; POINT MUTATION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOQUINONES; BIPHENYL COMPOUNDS; BORONIC ACIDS; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; HUMANS; LACTAMS, MACROCYCLIC; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; NITROPHENOLS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-BCR; PYRAZINES; PYRIMIDINES; SULFONAMIDES;

EID: 34548039481     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/sj.cdd.4402168     Document Type: Article

References (40)

1. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to ST1571. Blood 2003; 101: 690-698.
2. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 878-880.
3. Mahon FX, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J et al. MDR1 gene overepression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003; 101: 2368-2373.
4. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J et al. Multiple BCR-ABL kinase domain mutations confer poyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117-125.
5. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399-401.
6. Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129-141.
7. Kimura S, Naito H, Segawa H, Kuroda J, Yuasa T, Sato K et al. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 2005, 106: 3948-3954.
8. + leukemia cells in the central nervous system and cyclosporine A augments its in vivo activity. Blood 2007; 109: 306-314.
9. Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent' fraction. Blood 2006; 107: 4532-4539.
10. Holtz MS, Slovak ML, Zhang F, Sawyers CL, Forman, SJ, Bhatia, R. Imatinib mesylate (STI571) Inhibits gicwth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increasad proliferation. Blood 2002; 99: 3792-3800.
11. Komarova NL, Wodarz D. Drug resistance in cancer: Principles of emergence and prevention. Proc Natl Acad Sci USA 2005; 102: 9714-9719.
12. Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL et al. Dynamics of chronic myeloid leukemia. Nature 2005; 435: 1267-1270.
13. Huang DC, Strasser A. BH3-Only proteins-essential initiators of apoptotic cell death. Cell 2000; 103: 839-842.
14. Strasser A, O'Connor L, Dixit VM. Apoptosis signaling. Annu Rev Biochem 2000; 69: 217-245.
15. Aichberger KJ, Mayerhofer M, Krauth MT, Vales A, Kondo R, Derdak S et al. Low-level expression of proapoptotic: Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: Role of BCR/ ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds. Cancer Res 2005; 65: 9436-9444.
16. Nimmanapalli R, O'Bryan E, Kuhn D, Yamaguchi H, Wang HG, Bhalla KN. Regulation of 17-AAG-induced apoptosis: Role of Bcl-2, Bd-XL, and Bax downstream of 17-AAG-mediated down-regulation of Akt, Raf-1, and Src kinases. Blood 2003; 102: 269-275.
17. Tan TT, Degenhardt K, Nelson DA, Beaudoin B, Nieves-Neira W, Bouillet P et al. Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. Cancer Cell 2005; 7: 227-238.
18. Zhu H, Zhang L, Dong F, Guo W, Wu S, Teraishi F et al. Bik/NBK accumulation correlates with apoptosis-induction by bortezomlb (PS-341, Velcade) and other proteasome inhibitors. Oncogene 2005; 24: 4993-4999.
19. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S et al. Mechanism of apoptosis sensitiviy and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006; 10 375-388.
20. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-681.
21. Huang DC, Cory S, Strasser A. Bcl-2, Bcl-XL and adenovirus protein E1B19kD are functionally equivalent in their ability to inhibit cell death. Oncogene 1997; 14: 405-414.
22. + leukemic cells and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci USA 2006; 103: 14907-14912.
23. Strasser A, Harris AW, Huang DC, Krammer PH, Cory S. Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J 1995; 14: 6136-6147.
24. Kuribara R, Honda H, Matsui H, Shinjo T, Inukai T, Sugita K et al. Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors. Mol Cell Biol 2004; 24: 6172-6183.
25. Puthalakath H, Strasser A. Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ 2002; 9: 505-512.
26. Seward RJ, von Haller PD, Aebersold R, Huber BT. Phosphorylation of the pro-apoptotic protein Bim in lymphocytes is associated with protection from apoptosis. Mol Immunol 2003; 39: 983-993.
27. Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P, Rosen N. Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem 2002; 277: 39858-39866.
28. Ito T, Tanaka H, Kimura A. Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn. Eur H Haematol 2007: 78: 417-431.
29. Cortes J, Talpaz M, O'Brien S, Jones D, Luthra R, Shan J et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 2005; 11: 3425-3432.
30. Press RD, Love Z, Tronnes AA, Yang R, Tran T, Mongoue-Tchokote S et al. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML. Blood 2006; 107: 4250-4256.
31. Essafi A, Fernandez de Mattos S, Hassen YA, Soeiro I, Mufti GJ, Thomas NS et al. Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells. Oncogene 2005; 24: 2317-2329.
32. Ley R, Ewings KE, Hadfield K, Cook SJ. Regulatory phosphorylation of Bim: Sorting out the ERK from the JNK. Cell Death Differ 2005; 12: 1008-1014.
33. Obeng EA, Carlson LM, Gutman DM, Harrington Jr WJ, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006; 107: 4907-4916.
34. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabolar PE et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiency induces apoptosis via Bak/ Bax if Mcl-1 is neutralized. Cancer Cell 2006; 10: 389-399.
35. Gorre ME, Ellwood-Yen K, Chiosis G, Rosen N, Sawyers CL. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood 2002; 100: 3041-3044.
36. Letai A, Sorcinelli MD, Beard C, Korsmeyer SJ. Antiapoptotic BCL-2 is required for maintenance of a model leukemia. Cancer Cell 2004; 6: 241-249.
37. Cirinna M, Trotta R, Salomoni P, Kossey P, Wasik M, Perrotti D et al. Bcl-2 expression restores the leukemogenic potential of a BCR/ABL mutant defective in transformation. Blood 2000; 96: 3915-3921.
38. Jaiswal S, Traver D, Miyamoto T, Akashi K, Lagasse E, Weissman IL. Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias. Proc Natl Acad Sci USA 2003; 100: 10002-10007.
39. Bouillet P, Robati M, Bath M, Strasser A. Polycystic kidney disease prevented by transgenic RNA Interference. Cell Death Differ 2005; 12: 831-833.
40. Kuroda J, Kimura S, Segawa H, Sato K, Matsumoto S, Nogawa M et al. p53-independent anti-tumor effects of the nitrogen-containing bisphosponate zoledronic acid. Cancer Sci 2004; 95: 186-192.